Endothelin (ET), a potent vasoconstrictor peptide, is known to enhance the secretion of atrial natriuretic factor (ANF) by the heart. In the present study, we investigated the potency of ET isopeptides to stimulate ANF and brain natriuretic peptide (BNP) secretion in primary cultures of neonatal atrial myocytes, and we characterized the receptor mediating these effects. All ET isopeptides caused a twofold increase of ANF and BNP secretion with the following order of potency: ET-1P:ET-2>sarafotoxin 6b>>ET-3. Secretion of the natriuretic peptides was blocked by BQ-123, an ETAreceptor antagonist, but was not affected by either IRL-1620 or [Ala"3"""5]ET-1, two ETB-receptor agonists. ET receptors were localized by autoradiography on the surface of atrial myocytes, indicating that contaminating cells were not responsible for '251-ET-1 binding. Competition binding analyses were then used to assess the ET-receptor subtype on atrial myocyte membrane preparations. A high-affinity (100 pmol/L) binding site with high density (=1500 fmol/mg) was found to preferentially bind the ET isopeptides in the following order:
N atriuretic peptides found in the heart are now well recognized as hormones with potent actions at the level of the kidneys, the vasculature, and the adrenal glands, regulating salt and water homeostasis as well as blood pressure."2 Among the members of this peptide family, atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) are synthesized by atrial myocytes of the rat heart and are stored in atrial secretory granules. We have shown that ANF and BNP are present in the same secretory granules of the rat,3 and some investigators have found BNP in secretory granules of pig atria but not evenly distributed across the atrial wall. 4 Others have reported that BNP is not contained in all secretory granules of human atria. 5 These results may suggest that both peptides could be secreted concomitantly on stimulation.
The factors that affect ANF and BNP secretion by atrial myocytes are not fully known. The main in vivo stimulus of release appears to be mechanical stretching of the atrial wall. In a review by Ruskoaho et al, 6 only a few agents have been documented to enhance ANF release. Among them, endothelin (ET) appears to be one of the most potent. The ETs comprise a family of peptides with high homology.7 Among them are ET-1, ET-2, and ET-3, which have been cloned from mammalian banks, and the sarafotoxins (S6a, S6b, and S6c), which originate from venom of the asp Atractaspis engaddensis. These are all 21-amino-acid peptides with two disulfide-bond closed loops. ET-1, the principal peptide of the ET family, is strongly expressed in the vascular endothelium but also in other tissues in vivo. ET-2 and ET-3 have a more restricted expression, such as in the placenta or tumoral cells. 7 ETs have profound effects on cardiovascular regulation through their influence on the vasculature and kidney or via the secretion of other hormones. 5, 8 At the level of the heart,9 ETs act as inotropic and chronotropic agents, vasoconstricting coronary arteries and potentiating ANF release by myocytes. They affect ANF secretion in vivo as well as in isolated systems such as the perfused rat heart and neonatal atrial myocytes in culture.'0-14 In cardiac myocytes, ET activates various signal transduction pathways: inositol phosphate production, protein kinase C activation, or intracellular Ca21 mobilization. '5-18 ET and ANF counteract each other at different levels. ANF modulates in vivo the renal effects of ET'9 as well as its constrictor effect on aortic ring preparations. 20 Conversely, ET can decrease the cardiovascular and endocrine effects of ANF.21 ANF inhibits the stimulated release of ET by mesangi-a122 and endothelial cells23'24 but enhances it in parathyroid cells.25 ANF can block the mutagenesis induced by ET. 26 In view of these multiple interactions, it is therefore important to understand by which mechanisms ET triggers ANF secretion.
Until now, two ET receptors have been identified and cloned. 27 These receptors have been classified as ETA (with higher affinity for ET-1 than ET-3) and ETB (with similar affinity for ET isopeptides). Both are~430 amino acids long, have a molecular mass of :50 kD, and share high homology, particularly in the transmembrane domain, which is a potential G-protein binding site. ET receptors are apparently linked to phospholipase C and the inositol phosphate-diacylglycerol cascade as well as to phospholipase A2 and D. Pharmacologic tools have been developed to selectively activate or inhibit each receptor. Among these agents are BQ-123 and BQ-153, which are ETA-receptor antagonists,2829 and IRL-1620, BQ-3020, and [Ala"3'11"5]ET-1 (4Ala ET-1), which are ETB-receptor agonists. [30] [31] [32] The present study was designed to evaluate the impact of ET isopeptides on ANF and BNP secretion by atrial myocytes and to determine which ET-receptor subtype mediates their actions. Primary cultures of neonatal rat atrial myocytes were used to assess both ANF secretion and the receptor subtype. In addition, BQ-123, IRL-1620, and 4Ala ET-1 were used to characterize the ET-receptor subtype involved.
Materials and Methods Peptides
The ET isopeptides were purchased from Peninsula Laboratories, Belmont, Calif, and Bachem California, Torrance, Calif. BQ-123 was obtained from Peptides International Inc, Louisville, Ky. IRL-1620 was a generous gift from Dr N. Kamei, CIBA-GEIGY (Japan) Limited, Takarazuka, Japan. Rat ANF-(99-126) was synthesized by Hukabel, Longueuil, Quebec, Canada, and rat BNP-32 and its antiserum, which recognizes equally rat BNP-32 and -45, were bought from Peninsula Laboratories.
Atrial Myocyte Culture
Myocyte cultures were prepared from 4-day-old neonatal Sprague-Dawley rats (Charles River, St Constant, Quebec, Canada) as described by Shields and Glembotski.33 The animals were first injected intraperitoneally with 50 puL (50 U) heparin sulfate (Hepalean, Organon Canada Ltd, Toronto, Ontario, Canada). After decapitation, they were dipped in 70% ethanol, the chest was then opened, and the atria were removed with surgical forceps. Atria were collected from 3 litters (40 to 50 animals) and washed in 10 mL Joklik medium supplemented with 250 U heparin sulfate to remove red blood cells. They were digested at 37°C in 25 mL Joklik medium containing 0.1% collagenase (CLS 2, Worthington Biochemical Corp, Freehold, NJ) and 0.01% DNAse for 20 minutes with agitation (120 cycles per minute).
After incubation, the cells were dispersed by pipetting, and the remaining tissue was digested for another 20 minutes in 15 mL collagenase-DNAse solution. The dispersed cells were suspended in 10 mL fetal calf serum, filtered through a nylon mesh, centrifuged, and resuspended in complete serum-free medium (CSFM-1) plus 10% Nu-Serum IV (Collaborative Research Inc, Bedford, Mass).33 They were counted in a hematocytometer, diluted, and seeded in fibronectin-coated culture dishes at a density of 1.25 x 105 cells per square centimeter. Fibronectin was purified from rat plasma by gelatin-Sepharose 4B (Pharmacia LKB Biotechnology, Uppsala, Sweden) column34 and dialyzed against 0.02 mol/L sodium phosphate, pH 7.4, and 0.15 mol/L NaCl. The culture dishes were coated for 2 hours at room temperature with a solution of 60 ,ug/mL fibronectin at a density of 7.5 gtg/cm2. The plated cells were cultured at 37°C in 5% C02/95% air. The day after seeding, the medium was replaced with CSFM-233 supplemented with 10 ,ug/mL cytosine arabinofuronoside (Ara-C), which was removed from the medium after 3 days. The cells usually began beating in synchrony after 1 or 2 days in culture. After 5 to 6 days in culture, cells in 96-well plates were used for stimulation. The medium was changed for fresh CSFM-2 containing the different agents. All the peptides were dissolved in water or 0.01 mol/L acetic acid and were diluted from stock solution (10`mol/L) kept at -40°C. After 2 hours at 37°C, the medium was collected and kept frozen until assayed. Preliminary experiments have shown that secretion of both ANF and BNP were linear over a period of 8 hours. Addition of ET-1 to the medium also increases the amount of ANF and BNP in a linear fashion but at a higher level. In the present study, it is assumed that the maximal stimulatory response for all the secretagogues occurred at a similar time point.
Radioimmunoassay
Radioimmunoassays (RIAs) of ANF and BNP were performed with specific antisera. The cross-reactivities of ANF antiserum on BNP and the converse were <0.01%. All methods are fully described elsewhere.335 Five and 150 gL of medium were used without extraction for ANF and BNP RIA, respectively.
Atrial Membrane Preparations
Atrial membranes were prepared from both 4-day-old rats and neonatal atrial myocyte cultures. Membranes from 4-dayold rats were obtained by homogenization and centrifugation of atria as described by Liu et al. 36 In brief, atria were homogenized in 0.05 mol/L NaHCO3, pH 7.4, and 0.1 mmol/L phenylmethylsulfonyl fluoride (PMSF) with a Polytron (Brinkman, Rexdale, Ontario, Canada) (two times for 10 seconds) and centrifuged at 3000g for 10 minutes. The pellet was rehomogenized, and both supernatants were pooled and centrifuged at 40 000g for 15 minutes. The pellet was washed in 0.05 mol/L Tris-HCl, pH 7.4, recentrifuged at the same speed, and resuspended in the same buffer.
Cultured atrial myocytes in 10-cm plastic dishes were washed twice with 0.02 mol/L NaHCO3, pH 7.4, and 0.1 mmol/L PMSF and scraped in the same buffer (1 mL/60 cm2). The cells were homogenized in a Potter-Elvehjem homogenizer at 750 rpm with 10 strokes and centrifuged at 40 000g for 15 minutes. The pellet was resuspended in 0.05 mol/L Tris-HCI, pH 7.4. All membrane preparations were kept at -40°C until used. Preliminary experiments have shown that one freezing and thawing cycle does not affect the binding properties of the ET receptor. Proteins in the membrane preparations were measured by the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, Calif) with bovine serum albumin as standard. Atrial myocyte cultures give 4 to 5 gg protein per square centimeter.
Receptor-Binding Assay
The ET-receptor-binding properties of the membrane preparations were characterized by rapid filtration on a glass filter with iodinated ET-1 as tracer. ET-1 was radiolabeled by the lactoperoxidase method. 37 The monoiodinated peptide was then purified by reverse-phase high-performance liquid chromatography (HPLC) on a C18-Bondapak column with a linear 0.1% trifluoroacetic-acetonitrile gradient. The specific activity of the labeled ET-1 (1500 Ci/mmol) was assessed by self displacement.38 For saturation analysis, membrane proteins 10 tg) were incubated at room temperature for 90 minutes in the presence of increasing concentrations of iodinated ET-1 (20 000 to 800 000 cpm) in a total volume of 0.25 mL in 0.05 Tris-HCI, pH 7.2, 50 U/mL aprotinin, 0.1% bacitracin, 5 mmol/L MgCI2, and 0.5% bovine serum albumin. After 90 minutes of incubation at room temperature, the tubes (in duplicate) were filtered on a No. 34 glass filter (Schleicher & Schuell, Keene, NH) with a cell harvester (Brandel, Gaithersburg, Md). The filters were finally washed three times with 0.05 mol/L Tris, pH 7.2, and 0.15 mol/L NaCl. Before use, they were soaked in 5% dry skim milk (Carnation) to decrease nonspecific binding. Under these conditions, nonspecific binding due to absorption to the filters is <0.3% of total radioactivity. Radio-activity on the filters was counted in a gamma counter (LKB Wallac, Turku, Finland). Nonspecific binding to the membranes (<2%) was estimated in the presence of 10-6 mol/L ET-1. For competition analysis, membrane proteins (:::z10 ,g, which gives 10% to 15% binding) were incubated with 30 000 cpm of '5I-ET-1 in the presence of increasing concentrations of peptides (10-13 to 10-6 mol/L). All other parameters were identical to those in the saturation experiments.
Preliminary studies showed that binding was linear up to 25 ,ug of proteins. Binding equilibrium was reached between 60 and 90 minutes of incubation at room temperature. Analysis of iodinated ET-1 by reverse-phase HPLC after incubation indicated that <5% of the tracer was degraded. All the data were analyzed by the EBDA and LIGAND computer software of McPherson39 (Biosoft, Cambridge, UK).
Cross-linking of ET Receptor
One hundred micrograms of membranes was incubated in a total volume of 100 ,uL in 0.05 mol/L NaPO4, pH 7.4, and 0.15 mol/L NaCl (phosphate-buffered saline [PBS]) in the presence of 300 000 cpm of 125I-ET-1 with or without 10-6 mol/L ET-1, 10`6 mol/L BQ-123, or 10-f mol/L IRL-1620 for 90 minutes at room temperature. The samples were then centrifuged at 15 000 rpm for 10 minutes, and the supernatant was removed. The membrane pellet was resuspended in 50 ,uL PBS to which disuccinimidyl suberate (50 mmol/L in dimethyl sulfoxide) was added at a final concentration of 1 mmol/L. After 20 minutes, 1.25 pL of 2 mol/L Tris was incorporated to quench the cross-linker, and 5 minutes later, the membranes were collected by centrifugation and dissolved in sodium dodecyl sulfate (SDS) buffer for electrophoresis. Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 12% acrylamide gel according to the methodology of Laemmli.40 After electrophoresis, the gels were stained in 0.05% Coomassie R-250, dried, and exposed to X-Omat Kodak film (Eastman Kodak Co, Rochester, NY) for 10 to 20 days.
Autoradiography
Atrial myocytes were seeded in two-well culture chamber glass slides (Nunc Inc, Naperville, Ill). After 5 or 6 days in culture, the cells were incubated in 1 mL CSFM-2 containing 1x106 cpm/mL '25I-ET-1 for 2 hours on ice. Incubation was performed at low temperature to avoid internalization and degradation of the peptide. After incubation, the cells were washed once with CSFM-2 and twice with PBS, fixed for 10 minutes in 4% paraformaldehyde and 0.5% glutaraldehyde in PBS, washed once in PBS and once in 70% ethanol, and immersed 10 minutes in acetone at -20°C. The slides were then kept in 70% ethanol until they were immunostained. They were first incubated for 20 minutes in 1.5% normal goat serum (NGS) in PBS, washed, and then incubated overnight in ANF antiserum diluted 1:400 in 1.5% NGS in PBS. After washing the slides in PBS, the first antibody was revealed by the Vectastain ABC kit (Vector Laboratories, Burlingame, Calif) according to the manufacturer's instructions. Control experiments to reveal nonspecific staining were performed by saturation of the first antibody in the presence of excess (20 ,g) ANF-(99-126). To detect the bound radioactivity, the immunostained slides were dipped in K-5 emulsion (Ilford Scientific Product, Mabberley, UK) and exposed for 20 days.
ETAand ETB-Receptor Probes
Rat ETA-receptor cDNA generously donated by Dr Herbert Y. Lin, Whitehead Institute for Biochemical Research, Cambridge, Mass, was used as a cDNA probe.41 The rat ETB-receptor probe was prepared by polymerase chain reaction (PCR) amplification with first-strand cDNA from the rat lung. First-strand cDNA was synthesized by incubating 5 ,ug of total RNA in a 50-,Lp reaction mixture containing 50 mmol/L Tris-HCl (pH 8.3), 50 mmol/L KCI, 10 mmol/L MgCl2, 10 mmol/L dithiothrei-tol, 1 mmol/L dNTPs, 0.5 mmol/L spermidine, 1 ,ug oligo(dT) [12] [13] [14] [15] [16] [17] [18] (Pharmacia LKB Biotechnology), and 10 U/,g RNA avian myeloblastosis virus reverse transcriptase (Promega Corp, Madison, Wis) for 1 hour at 42°C. The tubes were then boiled for 5 minutes, and bovine pancreas ribonuclease (Pharmacia LKB Biotechnology) was added to give a final concentration of 1 ,g/mL and incubated for 30 minutes at 37C. Five microliters of first-strand cDNA was subjected to PCR amplification in a 50-pL reaction mixture containing 10 mmol/L Tris-HCl (pH 8.3), 1.5 mmol/L MgCl2, 50 mmol/LKCI, 0.1% Triton X-100, 200 pmol/L dNTPs, 100 pmol of each primer, and 2 U Thermus aquaticus DNA polymerase (Promega). PCR amplification was performed in an Easy Cycler (Ericomp, San Diego, Calif) programmed as follows: 5 minutes of initial denaturation at 95°C, then 30 cycles with 1 minute of denaturation at 95°C, 1 minute of annealing at 50°C, and 1 minute of elongation at 72°C with final elongation for 10 minutes at 72°C. A 494-bp ETB-receptor PCR product was obtained using a 5' forward primer (5'-CTTAATCCCTTTCA-GAAAACAGC-3) and a 3' reverse primer (5'-AAGCAG-GATTGCTTCTCCTCTAA-3'). located at nucleotides 766 to 788 and 1237 to 1259 of the coding sequence, respectively.42 This PCR product was then cloned into pGEM-7zf(+) plasmid (Promega). The sequence was determined by the Sanger method of dideoxy-mediated chain termination43 and was identical to the cloned rat ETB receptor. 42 Radiolabeled ETAand ETB-receptor cDNA probes were prepared by random-prime labeling,37 using [32P]dCTP (3000 Ci/mmol, Amersham Corp, Arlington Heights, Ill) and the Klenow fragment of DNA polymerase (Promega). 18S ribosomal RNA was analyzed with a specific oligonucleotide probe (5 '-CTTCCTCTAGATAGTCAAGTTCGACCGTCT-3 )44 labeled with T4 polynucleotide kinase (Pharmacia LKB Biotechnology) and [32P]ATP (3000 Ci/mmol, Amersham). The 32P-labeled probes were purified by chromatography using NACS cartridges (GIBCO-BRL, Burlington, Ontario, Canada).
Northern Blot Analysis
Total RNA was extracted from cultured neonatal atrial myocytes by the guanidium isothiocyanate-phenol-chloroform method. 45 The samples were resuspended in diethylpyrocarbonate-treated H20, and optical density was determined at 260 and 280 nm. Typically, a ratio of 1.6 to 1.75 was obtained. Total RNA samples (20 ,ug) were ethanol-precipitated, resuspended in 20 uL denaturation solution containing 1 x running buffer (20 mmol/L MOPS [pH 7.0], 6 mmol/L sodium acetate, and 1 mmol/L EDTA), 6% formaldehyde, and 50% formamide, and then heated for 15 minutes at 65°C before loading. RNA samples were run on 1.0% agarose gel containing 1 x running buffer and 6% formaldehyde. The samples were transferred from the gel to a Duralon-UV nylon membrane (Stratagene, La Jolla, Calif) by capillary action using 3 mol/L NaCl and 0.3 mol/L sodium citrate (20x standard saline citrate [SSC]). After blotting, the filters were completely dried, and RNA was fixed to the membranes by UV irradiation with UV Stratalinker (Stratagene). To verify the evenness of loading in each lane and to identify the location of the 18S and 28S ribosomal RNA species, the filters were stained with 0.02% methylene blue in 0.3 mol/L sodium acetate (pH 5.5), followed by rapid destaining in diethylpyrocarbonate-treated H20. After recording each of the ribosomal RNA positions, the membranes were destained in 0.1xSSC and 1% SDS for 15 minutes. They were prehybridized for 2 hours at 42°C in 50 mmol/L sodium phosphate buffer (pH 7.0) containing 5x SSC, 1% SDS, SxDenhardt's solution (SOxDenhardt's solution contains 1% Ficoll, 1% polyvinylpyrolidone, and 1% bovine serum albumin), 50% formamide, and 100 ug/mL sonicated salmon sperm DNA. Hybridization began with the addition of the 32P-labeled probe. It was carried out for 18 to 20 hours at 42°C. The membranes were washed three times in 12.5 mmol/L NaCl and 0.1% SDS at 42°C for 20 minutes. They were patted dry with paper towels, enveloped in plastic wrap, Peptide concentration (log M) FIG 1. Graph showing stimulation by endothelin (Et) isopeptides of atrial natriuretic factor (ANF) secretion by atrial myocytes. S6b indicates sarafotoxin 6b. Since basal ANF secretion varied from culture to culture from 600 to 1500 fmol per well for 2 hours, the results are expressed as percentage of changes in ANF secretion. These results are mean±SEM of four to six cell preparations with six to eight wells per preparation. Secretions of each peptide were compared with the lowest concentration by one-way ANOVA and the a posteriori Bonferroni t test. *P<.05. and exposed to Kodak XAR-5 film with intensifying screens at -70°C for 5 to 7 days.
Statistical Analysis
All the data are presented as the mean+SEM. Statistical analyses of ANF and BNP secretion were performed by one-way ANOVA followed by an appropriate a posteriori test as described in the legends of figures. A value of Pc.05 was considered significant. Correlations between two variables were analyzed by the Pearson product moment test. The statistical software SIGMASTAT (Jandel Scientific, San Rafael, Calif) was used in all cases.
Results
Since ANF secretion is reported to be enhanced by ET, we examined the potency of different ET isopeptides on this parameter in a cardiac myocyte culture system. Neonatal atrial myocytes were incubated for 2 hours in the presence of increasing concentrations of ETs. ANF and BNP were measured in the media by specific RIAs. Fig 1 shows the dose-response curve of ANF secretion in the presence of ET-1, ET-2, ET-3, and S6b. Basal secretion of ANF from one preparation to the other varied from 600 to 1500 fmol per well for 2 hours (920±100 fmol per well for 2 hours, n=9 cell preparations), and results were expressed as percentage of changes in ANF secretion. All four peptides doubled ANF secretion but with different potencies. ET-1 was the most potent, with an EC50 of 46 pmol/L. The potency of ET-2 (54 pmol/L) was comparable to that of ET-1. In both cases, responses doubled at 10-9 mol/L (203±3.7% for ET-1 and 200±3.9% for ET-2). S6b and ET-3 were less potent, with EC50s of 385 pmol/L and 14.1 nmol/L, respectively, and maximal responses at 10`8 and 10`mol/L, respectively (202±5.0% and 207±8.0%, respectively). The order of potency of the ET isopeptides was therefore as follows: ET-1=ET-2>S6b>>ET-3. High doses of ET isopeptides also showed a slight, although not significant when compared with the maximal stimulation, inhibition of ANF secretion. A similar situation was observed by Lew and Baertschi.46 In addition to chronotropic and inotropic effects, ET has been reported to have cytoxic effects.47 ET at high doses may therefore profoundly alter the metabolism of myocytes and consequently its secretory function. The availability of an ETA-receptor antagonist allowed us to test whether this compound could block ET-stimulated ANF secretion. BQ-123 in increasing doses significantly blocked ET-stimulated ANF secretion (Fig 2A) . A similar pattern of inhibition was seen when ANF secretion was stimulated by ET-2, S6b, or ET-3 ( Fig 2B) . We also investigated the potential stimulation of ANF secretion by IRL-1620, an ETB-receptor agonist ( Fig 3A) . Alone or in combination with ET-1, it had no effect on ANF secretion. Since BNP is present in rat atria and is stored in atrial secretory granules,3 we also examined simultaneous ANF and BNP secretion by atrial myocytes. As illustrated in Fig 3B, BNP secretion, measured by a specific RIA, always represented = 1% of basal or stimulated ANF secretion. This figure also depicts the effect of 4Ala ET-1, another ETB agonist, which did not modify basal or stimulated ANF and BNP secretion. As with ANF, BQ-123 blocked BNP secretion. Fig 4 illustrates the relation between secretions of ANF and BNP by atrial myocytes. Significant correlations were obtained for these two parameters, indicating that, under basal or ET-stimulated secretion, BNP is proportional to ANF and probably originates from the same source, the atrial secretory granules.
The order of potency of the ET isopeptides, the inhibition of secretion of the natriuretic peptides by BQ-123, and the lack of response to IRL-1620 and 4Ala ET-1 suggest that the ETA-receptor subtype is involved in the stimulatory action.
To verify the presence of the ETA receptor in atrial myocyte cultures, membranes were prepared from cultured cells as well as from the atria of 4-day-old animals. The latter preparations were used to verify that there was no major change in ET-receptor properties when the myocytes were put in culture. Atrial myocyte membrane preparations were also used to assess the binding properties of iodinated ET-1 by means of saturation curves (Fig 5) . Specific binding was saturated with 800 pmol/L of 125I-ET-1. Scatchard analysis of the data indicated the presence of a single class of binding sites with an affinity in the picomolar range. Three different membrane preparations were used to estimate the binding parameters: the apparent dissociation constant was 204±45 pmol/L, and the maximum density of binding sites (Bma) was 1280±380 fmol/mg protein.
Both atrial tissue and atrial myocyte membrane preparations were then examined in competition experiments with 125I-ET-1 as the tracer in conjunction with either ET-1, ET-2, ET-3, S6b, BQ-123, or IRL-1620 ( Fig 6) . The results of analysis of the curves are given in the Table. ET-1, ET-2, and S6b displaced 125I-ET-1 with very high and comparable affinity, and a high-affinity binding site was detected. ET-3 also displaced the tracer but with somewhat lower potency. With both S6b and ET-3, a second site was detected. BQ-123, the ETA antagonist, totally displaced iodinated ET-1 on the atrial myocyte preparations, but two sites of different affinities were found. Finally, IRL-1620 displaced = 10% of the tracer on myocyte preparations, indicating the possible presence of a very low density of ETB receptors. In atrial tissue preparations (Fig 6A) , a slightly different picture was seen: BQ-123 displaced 80% of the tracer, and IRL-1620 displaced =15%, suggesting the presence of a low proportion of ETB receptors. These results thus demonstrated only minor There was a significant linear relation (Fig 7) between the log of the EC50 (from results presented in Fig 1) and the Kds of ET-1, ET-2, S6b, and ET-3 (Table) , suggesting that this high-affinity binding site was directly related to ANF secretion. Logarithmic transformation of the EC50 may reflect the different experimental condi- Displacement by ETB-receptor agonist IRL-1620 was <15%. Affinities and densities when IRL-1620 was used could not be mathematically evaluated adequately.
were positive. Staining was more intense at the periphery of the nucleus, where storage granules are mainly located.48 Preincubation of the primary ANF antibody with ANF-(99-126) completely abolished the reaction (Fig 8B) . The location of the ET receptor was visualized by incubating the cells with 'PI-ET-1 and coating them with a photographic emulsion. The ET receptor will appear as black silver grains at the surface of cells, which may be positively stained. Only cells that stained positively for ANF demonstrated the presence of silver grains, which were distributed randomly all over the surface (Fig 8A) . Cells that did not stain possessed only a few grains corresponding to background (Fig 8A and  8E, arrowheads) . The silver grains were totally displaced by 10-6 mol/L ET-1 (Fig 8C) and 10-6 mol/L BQ-123 ( Fig 8D) isopeptides on atrial natriuretic factor secretion measured from the stimulation dose-response curves of Fig 1 and the Kd of high-affinity sites for ET-1, ET-2, sarafotoxin 6b, and ET-3 taken from the Table. Correlation was analyzed by the Pearson product moment test. 8E), confirming the results obtained by the displacement curves with the membrane preparations.
The molecular characteristics of the ET receptor were investigated by cross-linking and electrophoresis. '251-ET-1 was cross-linked with dissuccinimidyl suberate to the ET receptor and then analyzed by SDS-PAGE and autoradiography. Fig 9 illustrates that the crosslinked ET receptor had a molecular mass of ;50 kD. The labeled specific band was absent when the membrane was incubated with 10C6 mol/L ET-1 and BQ-123 but not with IRL-1620, confirming that the labeled receptor was of the ETA subtype.
Finally, to determine whether ETAand ETB-receptor genes were expressed in atrial myocytes, we performed Northern blot analysis on total RNA prepared from cultured cells using specific 32P-labeled cDNA probes (Fig 10) . Two mRNA bands of 4 and 5 kb were detected as expected for the ETA subtype. With a similar amount of total RNA, the ETB-receptor mRNA band of 4.5 kb could not be detected.
Discussion
In addition to the mechanical stretching of the atrial wall, many agents have been shown to consistently enhance in vivo the secretion of the natriuretic peptides by atrial myocytes. Among them, the effect of ETs in vivo or with perfused heart are well documented.6,10-13,49,50 However, in these experiments, it is difficult to dissociate stretch-induced secretion and its direct effects on atrial myocytes.
Neonatal atrial myocytes in culture are a good model for the evaluation of secretagogue independent of any hemodynamic modifications. In these cultured cells, calcium ionophores, a-adrenergic agents, and ET have been shown to be secretagogues of ANF. Indeed, these cells respond well to the presence of ET-1 with a twofold to fivefold ANF secretion increase. 14 nmol/L S6b showed comparable potency with the same dose of ET-1 to release ANF from perfused rat heart.
The cultured atrial myocyte system has also been used to assess intracellular mechanisms involved in the ET response. 15-However although many reports have been published on the characterization of ET receptors on cultured ventricular myocytes2,53 as well as on the presence of ET receptors and their expression in adult atrial tissue,7 754-57 no data are yet available on cultured neonatal atrial myocytes and their relation with natriuretic peptide secretion.
One of the major problems encountered with cultured cells is that the phenotype of the original tissue can be lost in culture. This problem was eliminated in the present study by comparing the binding properties of the ET receptor on atrial myocytes with those of the atrial tissue of 4-day-old rats from which the culture originated. As shown in the Table, there were no major differences in the affinities of the ET isopeptides between both membrane preparations, indicating that the phenotype in cultured cells was preserved. Moreover, receptor density was roughly equal, although the membrane preparations were obtained by different proto-cols. A minor difference was seen: atrial tissue possessed a slightly larger amount of ETB receptor compared with cultured atrial myocytes. This difference can be attributed to the fact that atrial tissue preparations contain membranes not only from myocytes but also from other cell types, such as endothelial cells originating from the coronary circulation, which are known to contain the ETB receptor. 58 Another important problem is purity of the culture. The addition of Ara-C, an antimitotic agent, to the culture medium greatly improved myocyte purity,59 and typically, the culture contained <5% of contaminating cells on the basis of anti-ANF immunostaining. The possibility that these contaminating cells possess the ET receptor and therefore affect the overall binding parameters was assessed by autoradiography. Cells that did not stain with ANF antiserum did not bind iodinated ET-1.
The ET receptor subtype on atrial myocyte membrane preparation was characterized by competition analysis with '25I-ET-1 as tracer and ET isopeptides as well as the ETB-receptor agonist IRL-1620 and the ETA-receptor antagonist BQ-123. The competition binding curves revealed high-affinity binding sites (100 pmol/L) for ET-1, ET-2, and S6b with high density (1500 fmol/mg). IRL-1620 displaced 10% of iodinated ET-1. As reported by Takai et al,31 the selectivity of this drug is 105 times higher for the ETB receptor than for the ETA receptor in porcine tissues. Therefore, the ETB-receptor subtype seems to be present in very low density in our myocyte membrane preparations. In contrast, BQ-123, the ETA antagonist with a 103 times greater selectivity for the ETA subtype,29 completely displaced '25I-ET-1, indicating a predominance of this ETA receptor. Displacement curves with ET-3, S6b, and BQ-123 should therefore behave according to a one-site model, corresponding to the ETA-receptor subtype. However, analysis of the data (Hofstee transformation) suggested the presence of a second lower-affinity binding site (20 nmol/L, Table) , which represented -25% of total receptors. Indeed, Panek et a155 have already observed that the ET binding site in adult rat atria does not behave exactly as an ETA receptor. Furthermore, this site is clearly distinct from the putative ETCreceptor subtype postulated by Emori et 25I-ET-3. Although one site was observed with 125-ET-1, two sites were seen with '25I-ET-3. In the absence of any experiments with specific receptor drugs, the author could only establish the presence of two sites without appropriate identification. On the basis of the order of affinity (ET-1.ET-2.S6b>ET-3) of the ET isopeptides, of displacement with an ETA antagonist, and of ETA-receptor mRNA expression, it can be concluded that the high-affinity binding site observed on atrial myocytes is most probably an ETA-like receptor.
However, the lack of displacement with IRL-1620 (:15%) and the proportion of low-affinity binding sites (:25%) suggest that some heterogeneity still exists that cannot be adequately classified with the pharmacologic tools presently available. The molecular mass of the ET receptor (-50 kD), measured by cross-linking of iodinated ET-1 and SDS-PAGE, is well within the range of molecular mass already reported (from 30 to 70 kD)27 and in fact corresponds to the mass of ET receptors calculated from their amino acid numbers. This technique, which also showed that the ET receptor does not appear to be degraded in small, less active fragments, does not allow discrimination between ET-receptor subtypes because both possess a similar mass.
All the results also supported the concept that the ETB-receptor subtype, if present in our cultured atrial myocyte preparation, is expressed in very low amounts that cannot be easily detected by available pharmacologic tools or by Northern blot analysis. ANE secretion by atrial myocytes was enhanced by the ET isopeptides, and the order of their potency was ET-NlET-2>S6b>>ET-3. Moreover, the ETA antagonist BQ-123 inhibited ANF secretion, whereas IRL-1620 and 4Ala ET-1, two ETB agonists, did not alter basal or ET-stimulated secretion. Therefore, we can assume that ANF secretion is mediated by activation of an ETA-like receptor. Indeed, a linear logarithmic relation was established between the potency of the ET isopeptides to enhance ANF secretion and their corresponding Kds on the high-affinity binding site. BNP secretion followed a pattern similar to ANF, indicating concomitant excretion. These findings confirm and further extend our previous results3 as well as other reports61,62 on BNP secretion.
ETs are synthesized and released mainly but not exclusively by the vascular endothelium.58 They are believed to act as paracrine hormones on surrounding cells, principally vascular smooth muscle cells. The heart contains and releases immunoreactive ET.6364 In the myocardium, endothelial cells of the capillaries and of the endocardium are in close juxtaposition to myocytes. It is therefore plausible that ETs have a direct and short-term action with inotropic and chronotropic results and modulate ANF and BNP secretion. Over a longer term, ETs enhance the expression of cardiac genes, such as myosin light chain, a-actin, ANF, and BNP. l65-67 Moreover, the elevation of ET expression in a pathological situation such as congestive heart fail-ure68 may be of prime importance in the control of secretion of the natriuretic peptides by the heart.
In conclusion, the present study demonstrates that the stimulation of natriuretic peptide secretion by ET is mediated through binding to the ETA receptor on the surface of atrial myocytes and further substantiates the potential role of ET in cardiovascular regulation.
